Cutaneous HPV linked to squamous cell carcinoma

Share this article:

Squamous cell carcinoma (SCC) was positively associated with antibodies to several types of cutaneous human papillomavirus (HPV) in a case control study.

Cutaneous HPV infection, which differs from the mucosal HPV infection associated with cervical cancer, has been suspected of being a risk factor for SCC. Dana E. Rollison, PhD, of the Department of Cancer Epidemiology at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, and colleagues investigated the association by studying 173 SCC cases and 300 controls who screened negative for skin cancer at a university dermatology clinic.

As the team reported in Cancer Epidemiology, Biomarkers & Prevention, antibodies against cutaneous HPV types in genera alpha, beta, gamma, mu, and nu in participants' blood samples were measured. In addition, tumor tissue from 159 of the SCC cases was tested for the presence of cutaneous HPV infection. The measuring of cutaneous HPV types in five different genera and the investigating of correlations between cutaneous HPV antibodies in the blood and HPV infection in the tumor made this study unique, pointed out Rollison in a statement issued by the Moffitt Cancer Center.

The researchers found that SCC was positively associated with seropositivity to any genus-beta HPV type. Type-specific associations with SCC were observed for HPV type 10 in genus alpha and HPV types 8 and 17 in genus beta. Additional associations were found between antibodies to beta HPV types 5 and 24 when SCC cases with those same HPV types in their tumors were compared with controls.

Identifying the role of cutaneous HPV infection in SCC may lead to improved characterization of high-risk individuals and the development of novel prevention strategies, noted Rollison and associates.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Disparities persist in early stage breast cancer treatment

Despite its acceptance as standard of care neary 25 years ago, barriers still exist that preclude patients from receiving breast conserving therapy (BCT), according to research presented at the ASCO 2014 Breast Cancer Symposium.

Adding drugs to standard chemotherapy improves response in triple-negative breast cancer

Adding carboplatin and/or bevacizumab to the standard treatment regimen significantly improved pathologic complete response rates in patients with triple-negative breast cancer, according to a new phase 2 study.

Novel drug safe for patients with leukemia

Results of a phase I clinical trial showed that a new drug targeting mitochondrial function in human cancer cells was safe and showed some efficacy in a heavily pretreated cohort of patients.